Meeting
2023 ASCO Annual Meeting
The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: Preclinical mouse model and phase I/IIa clinical study.
Authors
Myeong Geun Choi
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mokdong Hospital, College of Medicine, Ewha Womans University, Seoul, Seoul, South Korea
Myeong Geun Choi , Gun Woo Son , Dae-Hyun Ko , Wonjun Ji , Jin Kyung Rho , Jae Cheol Lee , Yong Man Kim , Jae Seob Jung , Paul Y. Song , Byeong Gon Yoon , Jong-min Jo , Mi Young Choi , Chang-Min Choi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04872634
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9057)
DOI
10.1200/JCO.2023.41.16_suppl.9057
Abstract #
9057
Poster Bd #
45
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1/2a trial of nadunolimab, a first-in-class fully humanized monoclonal antibody against IL1RAP, in combination with cisplatin and gemcitabine (CG) in patients with non-small cell lung cancer (NSCLC).
First Author: Astrid Paulus
Poster
2022 ASCO Annual Meeting
Neoadjuvant and adjuvant capmatinib in resectable non–small cell lung cancer with MET exon 14 skipping mutation or high MET amplification: GEOMETRY-N trial.
First Author: Jay M. Lee
Poster
2017 ASCO Annual Meeting
Nivolumab (nivo) + nab-paclitaxel (nab-P) + carboplatin (C) in patients (pts) with non-small cell lung cancer (NSCLC): Interim results from a multicenter phase I study.
First Author: David Michael Waterhouse
Poster
2024 ASCO Annual Meeting
Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping mutations (METex14).
First Author: Mariana da Rocha Almeida Brandao